April 2022 edition of Australian Prescriber out now

Medicines for long-term obesity management

Genes are part of the cause of severe obesity and this explains why some people gain more weight than others. Professor Joseph Proietto from the University of Melbourne writes how medicines can help manage obesity. Medicines are particularly important in the maintenance of weight loss.

Assessing skin reactions to medicines

Some skin reactions to medicines can be severe and even life-threatening. Assistant Professor Ana Copaescu from the McGill University Health Centre and Associate Professor Jason Trubiano from the Department of Medicine, Austin Health review the assessment of severe skin reactions. A detailed clinical history and drug timeline are needed to find the culprit medicines. While alternative drugs are available for the majority of conditions, structurally similar medicines should usually be avoided.

Antidepressants and adolescents

For adolescents, antidepressants can be effective for anxiety and obsessive compulsive disorder but less so for major depressive disorder. Conjoint Professor Philip Hazell from the School of Medicine, University of Sydney reviews the limited evidence around the use of antidepressants for adolescents.

Troponins in myocardial infarction and injury

Detecting troponins in the blood was once a clear sign of acute coronary syndrome. Today assays are 1000 times more sensitive and their interpretation is different. Emeritus Professor Julia Potter from the Australian National University Medical School in Canberra and co-authors review the use of troponin detection in the diagnosis of myocardial infarction and injury.

Oral antivirals for mild-moderate COVID-19

A range of treatment options is now available for COVID-19. However, the clinical trial data are limited, and mostly prior to the emergence of the Omicron variant. Prof Ian Coombes from the Royal Brisbane and Women’s Hospital and co-authors write that the available evidence presents a challenge to the use of these medicines. Rapid approvals of these treatments mean postmarketing surveillance is crucial to ensure any benefits are derived without harm.

Also in this issue:

New drugs approved by the TGA: Casirivimab and imdevimab, Molnupiravir, and Nirmatrelvir and ritonavir for COVID-19, SARS-CoV-2 rs (NVX-CoV-2373) vaccine for prevention of COVID-19, fostemsavir for HIV-1 infection, lanadelumab for hereditary angioedema, ravulizumab for paroxysmal nocturnal haemoglobinuria


Media contact

Bernadette Withers: 0419 618 365 or [email protected]